Baricitinib tablets (Olumiant, adults) | GlobalRPh Renal Dosing Master

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Baricitinib tablets (Olumiant, adults) - selected U.S. label sections

Product / population: Adult OLUMIANT oral tablets. The indications below must not be combined.
Renal measure: eGFR in mL/min/1.73 m2; indication-specific tables

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Rheumatoid arthritis - renal dose

eGFR	Oral dose
60 to below 90	2 mg once daily
30 to below 60	1 mg once daily
Below 30	Not recommended

Alopecia areata - renal dose

At eGFR 30 to below 60, reduce a 2 mg daily regimen to 1 mg daily, or a 4 mg daily regimen to 2 mg daily. Below 30, use is not recommended.

COVID-19 - adult renal dose

eGFR	Oral dose
60 to below 90	4 mg once daily
30 to below 60	2 mg once daily
15 to below 30	1 mg once daily
Below 15, dialysis, end-stage disease or acute kidney injury	Not recommended

Review the separate indication, treatment-duration and drug-interaction instructions.

Source revision: Revision not captured; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=866e9f35-9035-4581-a4b1-75a621ab55cf

Scope: Local label summary; independent clinical review pending. Not a two-source validated protocol. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

Baricitinib tablets (Olumiant, adults) - selected U.S. label sections

Adult OLUMIANT oral tablets. The indications below must not be combined.

Renal method: eGFR in mL/min/1.73 m2; indication-specific tables
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

Official source

Baricitinib tablets (Olumiant, adults) - selected U.S. label sections

Adult OLUMIANT oral tablets. The indications below must not be combined.

Method: eGFR in mL/min/1.73 m2; indication-specific tables

Rheumatoid arthritis - renal dose Alopecia areata - renal dose COVID-19 - adult renal dose Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope Baricitinib tablets (Olumiant, adults) - selected U.S. label sections

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=866e9f35-9035-4581-a4b1-75a621ab55cf

Product and population scope

Adult OLUMIANT oral tablets. The indications below must not be combined.

RDM32-baricitinib-olumiant-scope · Source section: Editorial scope for the selected U.S. labelRenal section finder

Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official Compare this source

Baricitinib tablets (Olumiant, adults) - selected U.S. label sections

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Adult OLUMIANT oral tablets. The indications below must not be combined.

Renal method: eGFR in mL/min/1.73 m2; indication-specific tables
Source date: Revision not captured; retrieval date is not the revision date.
Retrieved: 2026-09-05

Local label summary; independent clinical review pending. Not a two-source validated protocol.

Rheumatoid arthritis - renal dose

eGFR	Oral dose
60 to below 90	2 mg once daily
30 to below 60	1 mg once daily
Below 30	Not recommended

RDM32-baricitinib-olumiant-1 · Source locator: 2.6, Table 3; 8.7

Alopecia areata - renal dose

At eGFR 30 to below 60, reduce a 2 mg daily regimen to 1 mg daily, or a 4 mg daily regimen to 2 mg daily. Below 30, use is not recommended.

RDM32-baricitinib-olumiant-2 · Source locator: 2.6, Table 4; 8.7

COVID-19 - adult renal dose

eGFR	Oral dose
60 to below 90	4 mg once daily
30 to below 60	2 mg once daily
15 to below 30	1 mg once daily
Below 15, dialysis, end-stage disease or acute kidney injury	Not recommended

Review the separate indication, treatment-duration and drug-interaction instructions.

RDM32-baricitinib-olumiant-3 · Source locator: 2.6, Table 5; 8.7

Source-specific limits

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Source identity and provenance

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=866e9f35-9035-4581-a4b1-75a621ab55cf
Retrieved: 2026-09-05
DailyMed Set ID: 866e9f35-9035-4581-a4b1-75a621ab55cf
Renal-function method: eGFR in mL/min/1.73 m2; indication-specific tables
Source date/version: Revision not captured; retrieval date is not the revision date.
Hash meaning: SHA-256 identifies this local summary, not original SPL XML or a label PDF.
Local summary SHA-256: e1b1bf2ba8e792d953e0de2bcb28fb5570236029d3f1d4f1f6d1715ffe6db717

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=866e9f35-9035-4581-a4b1-75a621ab55cf
Source retrieval: 2026-09-05. This is not the source publication or label revision date.
Original source type: multisource addition
Local text SHA-256: 5d489cf2e6ab5c6b85a26f9b8c769a6d978dba0d8fc034bbb43c5de912451493
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report